top of page



Funded by the European Union

Funded by the European Union´s Horizon Europe Research and Innovation Programme under Grant Agreement N. 101137192

The fight against global health threats from viral diseases takes a big step forward with AVITHRAPID "Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases". 

This ambitious project aims to create a pipeline of promising antiviral drugs built on existing small molecules with proven effectiveness against various viruses. These molecules will be rapidly developed into new treatments to combat emerging infectious diseases with pandemic potential.
More than just discovery, AVITHRAPID will also conduct a Phase 2a clinical trial. This trial will focus on a specific small molecule designed to fight the Zika virus.

The project is a powerful collaboration. AVITHRAPID brings together 18 research institutions and companies from 8 different countries. This collaboration ensures a wide range of expertise and approaches are used in the fight against viruses.

EuResist Network is part of WP3 Clinical development with its expertise in data management and support to clinical trials management.
The AVITHRAPID project started in January 2024 with a duration of 54 months and a budget of 7.5 million EUR. 


The main goal of AVITHRAPID is to find new antiviral drugs that work against a wide range of viruses. These drugs could be used to treat people during outbreaks and epidemics. The project will focus on finding new uses for existing drugs that are already known to be safe and effective. Scientists will use a logical approach to test these drugs in the lab before giving them to people.

By coordinating cutting-edge capacities and expertise already available in Europe AVITHRAPID will focus on specific objectives:
•    Supporting pandemic preparedness by provision of novel approaches for the development of antivirals using sophisticated computational methods in combination with experimental validation.
•    Joint development and optimization of pre-clinical candidates based on an available set of small molecules addressing various viral targets with a focus on broad-spectrum applicability
•    Establish a complete pre-clinical drug discovery pipeline based on the research activities within AVITHRAPID, that allows to react rapidly in case of novel viral infections with pandemic potential.


  1. Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V.

  2. Chelonia SA

  3. First Health Pharmaceuticals B.V.

  4. Instituto de Medicina Molecular Joao Lobo Antunes (iMM)

  5. Institut national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE)

  6. Università degli Studi della Tuscia (UNITUS)

  7. Universita degli Studi di Siena (UNISI)

  8. Elettra Sincrotrone Trieste SCOA

  9. Latvian Institute of Organic Synthesis (LIOS)

  10. Université de Tours (UT)

  11. University of Naples Federico II (UNINA)

  12. Swiss Tropical and Public Health Institute (Swiss TPH)

  13. Instituto Nazionale per le Malattie Infettive Lazzaro Spallanzani-Istituto di ricovero e cura a carattere scientifico (INMI)

  14. Università degli studi di Cagliari

  15. Università degli Studi di Roma “Tor Vergata”

  16. Dompé farmaceutici SpA

  17. Euresist Network GEIE

  18. VSB –Technical University of Ostrava

bottom of page